Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Celldex Therapeutics, Inc. (NASDAQ:CLDX) has received an average rating of “Moderate Buy” from the nine research firms that are presently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $62.25.

Several equities research analysts recently commented on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $67.00 price target on shares of Celldex Therapeutics in a research report on Monday, September 16th. Wells Fargo & Company upgraded Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 26th. HC Wainwright reiterated a “buy” rating and set a $80.00 price target on shares of Celldex Therapeutics in a report on Wednesday, November 20th. Wolfe Research downgraded Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a research note on Friday, September 27th. Finally, The Goldman Sachs Group initiated coverage on Celldex Therapeutics in a research note on Monday, September 30th. They set a “neutral” rating and a $45.00 target price on the stock.

Celldex Therapeutics Price Performance

CLDX stock opened at $27.23 on Tuesday. The firm has a market cap of $1.81 billion, a PE ratio of -10.60 and a beta of 1.60. Celldex Therapeutics has a 12 month low of $22.93 and a 12 month high of $53.18. The firm has a 50 day simple moving average of $28.55 and a 200 day simple moving average of $34.30.

Insider Activity at Celldex Therapeutics

In related news, CEO Anthony S. Marucci purchased 11,500 shares of the firm’s stock in a transaction on Monday, November 11th. The shares were bought at an average cost of $26.82 per share, for a total transaction of $308,430.00. Following the transaction, the chief executive officer now directly owns 40,284 shares of the company’s stock, valued at approximately $1,080,416.88. This trade represents a 39.95 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 3.80% of the stock is owned by corporate insiders.

Institutional Trading of Celldex Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. CANADA LIFE ASSURANCE Co boosted its position in shares of Celldex Therapeutics by 26.4% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock valued at $192,000 after acquiring an additional 955 shares in the last quarter. California State Teachers Retirement System grew its stake in shares of Celldex Therapeutics by 13.5% in the 1st quarter. California State Teachers Retirement System now owns 58,403 shares of the biopharmaceutical company’s stock valued at $2,451,000 after purchasing an additional 6,929 shares during the period. DNB Asset Management AS raised its holdings in shares of Celldex Therapeutics by 47.2% in the 2nd quarter. DNB Asset Management AS now owns 7,872 shares of the biopharmaceutical company’s stock worth $292,000 after buying an additional 2,523 shares in the last quarter. Mirador Capital Partners LP raised its holdings in shares of Celldex Therapeutics by 7.3% in the 2nd quarter. Mirador Capital Partners LP now owns 112,379 shares of the biopharmaceutical company’s stock worth $4,159,000 after buying an additional 7,620 shares in the last quarter. Finally, Assenagon Asset Management S.A. lifted its position in shares of Celldex Therapeutics by 53.0% during the 2nd quarter. Assenagon Asset Management S.A. now owns 139,162 shares of the biopharmaceutical company’s stock worth $5,150,000 after buying an additional 48,231 shares during the period.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.